These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37949157)

  • 1. CASP1 is a target for combination therapy in pancreatic cancer.
    Wang X; Chen Z; Nie D; Zeng X; Zhong M; Liu X; Zhong S; Wang L; Liao Z; Chen C; Li Y; Zeng C
    Eur J Pharmacol; 2023 Dec; 961():176175. PubMed ID: 37949157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E3 ubiquitin ligase UBR5 promotes gemcitabine resistance in pancreatic cancer by inducing O-GlcNAcylation-mediated EMT via destabilization of OGA.
    Du Y; Yang Z; Shi H; Chen Z; Chen R; Zhou F; Peng X; Hong T; Jiang L
    Cell Death Dis; 2024 May; 15(5):340. PubMed ID: 38755129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells.
    Duong HQ; Hwang JS; Kim HJ; Kang HJ; Seong YS; Bae I
    Int J Oncol; 2012 Sep; 41(3):855-61. PubMed ID: 22710732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway.
    Liu Y; Bi T; Liu L; Gao Q; Shen G; Qin L
    Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):615-622. PubMed ID: 30683944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer.
    Fan K; Fan Z; Cheng H; Huang Q; Yang C; Jin K; Luo G; Yu X; Liu C
    Cancer Med; 2019 Oct; 8(13):5903-5915. PubMed ID: 31426130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
    Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
    Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of the intrinsic apoptosis pathway is involved in Notch-induced chemoresistance to gemcitabine in pancreatic cancer.
    Du X; Zhao YP; Zhang TP; Zhou L; Chen G; Wang TX; You L; Shu H
    Arch Med Res; 2014 Jan; 45(1):15-20. PubMed ID: 24316112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperthermia inhibits the motility of gemcitabine-resistant pancreatic cancer PANC-1 cells through the inhibition of epithelial-mesenchymal transition.
    Jin H; Zhao Y; Zhang S; Yang J; Zhang X; Ma S
    Mol Med Rep; 2018 May; 17(5):7274-7280. PubMed ID: 29568909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation.
    Ricciardiello F; Gang Y; Palorini R; Li Q; Giampà M; Zhao F; You L; La Ferla B; De Vitto H; Guan W; Gu J; Zhang T; Zhao Y; Chiaradonna F
    Oncogene; 2020 May; 39(20):4103-4117. PubMed ID: 32235891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine.
    Dai S; Peng Y; Zhu Y; Xu D; Zhu F; Xu W; Chen Q; Zhu X; Liu T; Hou C; Wu J; Miao Y
    Biomed Pharmacother; 2020 Jan; 121():109521. PubMed ID: 31689601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.
    Allison Logan S; Brissenden AJ; Szewczuk MR; Neufeld RJ
    Drug Des Devel Ther; 2017; 11():2239-2250. PubMed ID: 28814832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory Effect of Oat Bran Ethanol Extract on Survival and Gemcitabine Resistance of Pancreatic Cancer Cells.
    Kim M; Mun JG; Lee HJ; Son SR; Lee MJ; Kee JY
    Molecules; 2019 Oct; 24(21):. PubMed ID: 31652886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro.
    Liu DL; Bu H; Li H; Chen H; Guo HC; Wang ZH; Tong HF; Ni ZL; Liu HB; Lin SZ
    Int J Oncol; 2012 Apr; 40(4):1049-57. PubMed ID: 22159556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK.
    Patel GK; Khan MA; Bhardwaj A; Srivastava SK; Zubair H; Patton MC; Singh S; Khushman M; Singh AP
    Br J Cancer; 2017 Feb; 116(5):609-619. PubMed ID: 28152544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approaches.
    Ashrafizadeh M; Luo K; Zhang W; Reza Aref A; Zhang X
    Environ Res; 2024 Jan; 240(Pt 2):117443. PubMed ID: 37863168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of chemoresistance-related mRNAs based on gemcitabine-resistant pancreatic cancer cell lines.
    Zhou J; Zhang L; Zheng H; Ge W; Huang Y; Yan Y; Zhou X; Zhu W; Kong Y; Ding Y; Wang W
    Cancer Med; 2020 Feb; 9(3):1115-1130. PubMed ID: 31823522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
    Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX
    J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of gemcitabine and Triapine by calcium carbonate nanoparticles against chemoresistant pancreatic cancer.
    Zhao Y; Zheng Y; Zhu Y; Ding K; Zhou M; Liu T
    Int J Pharm; 2023 Apr; 636():122844. PubMed ID: 36925025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
    Pan MR; Hsu MC; Luo CW; Chen LT; Shan YS; Hung WC
    Oncotarget; 2016 Sep; 7(38):61136-61151. PubMed ID: 27531902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
    Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
    Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.